LAUSR

The widespread deaths of tuberculosis from many decades demands an urgent need for the development of novel anti-tubercular scaffolds that are more potent and highly selective with lower cytotoxicity. Isatin hybrids are endowed with an extensive range of biological activities. Hybridization of isatin with various heterocyclic moieties such as benzofuran, coumarin, tetrahydropyrimidine, quinoline, and well-known drugs like Moxifloxacin, Ciprofloxacin, and so on may provide promising anti-tubercular candidates. This review focuses on the recent developments of isatin-based hybrids possessing potential anti-tubercular activity along with the novel drugs under various phases of clinical trials for the treatment of tuberculosis. The structure-activity relationships are also discussed to provide insights into the potential anti-tubercular candidates.